
|Articles|March 15, 2006
SCORE investigators update, expand enrollment criteria
Madison, WI?Investigators expanded the eligibility criteria of the SCORE study, a multicenter, randomized clinical trial designed to investigate the safety and efficacy of standard care versus intravitreal triamcinolone acetonide (IVTA) injections for the treatment of macular edema associated with central and branch retinal vein occlusion. The broader standards will accommodate a patient population more closely matched to those seen in the practice setting.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
US FDA awards Epion Therapeutics EpiSmart cross-linking system Fast Track designation
2
Abeona Therapeutics’ ABO-503 chosen for FDA's Rare Disease Endpoint Advancement Pilot Program
3
Treating myopia today: US-focused treatments, challenges, and global insights
4
FDA clears BVI’s FineVision HP trifocal IOL for the US market
5